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ABSTRACT 
 
This article aims to provide surgeons with a practical, clinical overview of different 
IRUPVRIµDUWKULWLV¶± a term encompassing most of the joint pathology causing 
joint symptoms or dysfunction. Conventionally, arthritis can be non-inflammatory 
(osteoarthritis) or inflammatory (crystal and autoimmune arthropathies). Septic 
arthritis is an important differential diagnosis when patients present with tender, 
swollen joints but is not covered in detail here. Common symptoms and signs in 
patients with different types of arthritis are reviewed, as well as aetiology and 
pathogenesis. Non-surgical treatment is described, with particular reference to 
the inflammatory arthropathies since the new, effective biologic treatments are 
particularly important where surgery is planned or patients present with 
suspected sepsis. Diagnosis of inflammatory arthritis (particularly in children) 
may be delayed and in an era of effective treatment it is important that all 
clinicians involved in musculoskeletal medicine and surgery are aware of 
potential differential diagnoses for joint pain and deformity. Good communication 
between rheumatologists and surgeons in managing different forms of arthritis is 
especially important. 
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OSTEOARTHRITIS 
 
Osteoarthritis (OA) is not a single disease or process; rather it is the outcome of 
the range of processes leading to pathological, structural and eventually 
symptomatic failure of one or more synovial joints. Recently a paradigm shift has 
moved the conception of OA from an exclusively degenerative condition of old or 
worn joints to an emphasis on OA as a dynamic, remodelling and regenerative 
condition. OA is the commonest type of arthritis and the leading cause of 
disability in those over the age of 65 years in developed countries. It may be 
classified as primary (idiopathic) or secondary to other processes such as 
trauma, congenital/developmental, mechanical or local factors (for example 
obesity or hypermobility) or as a sequelae of other inflammatory arthritides.  
 
OA involves all tissues in the joint ± initially there is loss of proteoglycan from the 
matrix of articular cartilage resulting in fibrillation, fissuring and degeneration. In 
more advanced disease, cartilage loss is such that the articulating surface is 
subchondral bone (eburnation). There is increased bone remodelling with 
subchondral osteosclerosis and cyst formation, articular surface deformity and 
osteophyte formation. Varying degrees of synovial inflammation and ligament 
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degeneration may also occur and OA is accompanied by peri-articular muscle 
wasting and biomechanical changes. These pathological processes lead to the 
characteristic x-ray (XR) features (FIGURE 1). There is often poor correlation 
between XR changes and symptoms. OA has multiple aetiological factors with 
gender, age and genetic factors increasing susceptibility and more local factors 
such as joint biomechanics, obesity, trauma and muscle weakness determining 
the site and severity of the disease. 
 
OA can affect any synovial joint and typical presenting features are mechanical 
pain in joints (worse with activity or weight bearing), joint stiffness and deformity. 
Spinal OA may cause neurological symptoms such as radiculopathy and spinal 
stenosis. 
 
Treatment is currently symptomatic ± medical therapies aim to control pain and 
physiotherapy maintains mobility, muscle strength and biomechanical integrity of 
the joint. In advanced disease with joint failure (disabling joint pain - particularly 
nocturnal ± and loss of joint function and deformity) management is surgical.  
Groups investigating the role of inflammation in the pathogenesis of OA have 
identified some potential therapeutic targets but current trial data show limited 
efficacy. There is increasing evidence that exercise has a crucial role to play in 
symptomatic management and explaining the importance of reducing obesity and 
promoting exercise to patients may help prevent OA progression. 
 
 
CRYSTAL ARTHROPATHIES 
 
Arthritis, both acute and chronic, can be caused by crystal deposition in joints. 
Gout is characterised by hyperuricaemia and monosodium urate crystal 
deposition; typically this is in peripheral joints, where the crystals can precipitate 
at cooler temperatures. Classically this will manifest in the great toe, but 
commonly also in the knee and ankle, wrist, hand and any joints affected by OA. 
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The crystals trigger acute episodes of cytokine release and consequent 
neutrophilic inflammation. The patient experiences excruciating joint pain, which 
typically starts in the early hours of the morning. The affected joints are often 
swollen and erythematous with patients unable to weight bear on them. Where 
hyperuricaemia and gout are chronic, urate may be present as macroscopic 
deposits (tophi) around joints or in cartilaginous structures such as the ear. Urate 
may also accumulate in the kidney causing at micro-level, urate nephropathy and 
at macro level, urate calculi. 
 
Urate is a by-product of purine metabolism and normally excreted through the 
kidneys. A minority of people with gout produce excess urate but much more 
commonly gout results from the under-excretion of urate. This may be due to 
renal failure, concurrent drug therapy, particularly aspirin and thiazide diuretics 
and alcohol intake. Hyperuricaemia is probably under-recognised and not 
everyone with hyperuricaemia has gout. Diagnosis of acute gout is on typical 
history and presentation, high serum urate (although this may paradoxically lower 
in acute attacks, as urate crystals precipitate in the extravascular space) and by 
demonstration of the typical negatively birefringent needle-shaped urate crystals 
in joint aspirate under polarised light microscopy. A key differential for an acute 
monoarthritis is septic arthritis, which would be diagnosed on synovial fluid 
microscopy and culture, highlighting the importance of joint aspiration.  
 
Treatment of gout involves lifestyle factor modification - to avoid high purine 
foods e.g. meat and shellfish, reduce alcohol & fructose intake (fructose 
increases serum uric acid by increased purine breakdown and increased purine 
synthesis) and avoid obesity. Precipitating medicines such as aspirin and 
diuretics should be avoided but this is often not possible. Acute gout is treated 
symptomatically by aspiration and injection of affected joints with corticosteroids 
and systemic administration of non-steroidal anti-inflammatory drugs (NSAID), 
low-dose colchicine or low-dose oral prednisolone (particularly where patients 
have comorbidity and NSAID or colchicine are contraindicated). Long-term 
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treatment of hyperuricaemia is with xanthine oxidase inhibitors such as 
allopurinol or febuxostat, which act to reduce serum urate levels. Lesinurad, a 
uric acid transport inhibitor, has just been licensed as an add-on therapy for 
patients whose urate levels are unsatisfactory despite first-line therapy, though it 
is not yet recommended by NICE. Recent work has demonstrated involvement of 
interleukin-1 (IL-1) pathways in gout and treatment with Anakinra (IL-1 receptor 
antagonist) shows promising results. It is worth noting that, on initiation, these 
treatments may paradoxically trigger a flare of gout and must always be started 
alongside prophylactic treatment such as NSAID or low-dose colchicine for 
around 3 months.  
 
Pseudogout or calcium pyrophosphate dehydrogenase (CPPD) arthropathy is the 
result of calcium pyrophosphate deposition in joint tissues, which triggers 
inflammation in a similar way to gout. This acute arthritis is commoner in older 
people and often poly-arthritic. It is associated with chondrocalcinosis on XR 
particularly in the knee and the wrist (FIGURE 2). Diagnosis is based on clinical 
presentation, typical XR appearances and the demonstration of positively 
birefringent, rhomboid crystals under polarised light. Aetiology is unknown but 
CPPD can be associated with haemochromatosis and acromegaly and in 
younger patients these conditions should be actively excluded. Hydroxyapatite is 
the third type of crystal arthropathy, commonest in older women and recognised 
as a cause of destructive shoulder arthritis, classically described as the 
µ0LOZDXNHHVKRXOGHU syndrome¶In this syndrome there often is significant 
humeral head destruction, CPPD deposits and rotator cuff tears. Treatment of 
both is symptomatic with NSAIDs, intra-articular steroid injections, physiotherapy 
and surgery where joint failure supervenes. 
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RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is a destructive, autoimmune arthritis that affects 1% of 
the adult population; women three times more commonly than men. It can occur 
at any age, but most often between the ages of 40 ± 50. Risk factors include 
SUHVHQFHRIWKH³VKDUHGHSLWRSH´DVHTXHQFHRIDPLQRDFLGVRQWKH+/$-
DRB1 chain - chromosome 6), a personal or family history of autoimmune 
disease, and smoking.  
 
RA principally affects synovial joints, but is a systemic inflammatory disorder 
affecting structures beyond the joints including for example, skin (rheumatoid 
nodules, pyoderma gangrenosum), lungs (fibrosis), mucous membranes 
GU\QHVV³VLFFDV\QGURPH´H\HVHSLVFOHULWLVVFOHULWLVDQGEORRGYHVVHOV
(vasculitis). Classically the arthritis involves the small joints of hands and feet, but 
large joints are also involved, either in addition, or alone. Pathologically, the 
affected joints develop a cKURQLFDOO\LQIODPHGRYHUJURZQ³WXPRXU-OLNH´V\QRYLXP
(pannus) that destroys cartilage and bone.  
 
RA remains a clinical diagnosis but the most recent international diagnostic 
criteria (2010) include synovitis of at least one joint, high acute phase markers, 
positive Rheumatoid Factor and/or positive anti-cyclic citrullinated peptide (CCP) 
antibodies and symptoms persisting beyond 6 weeks, not better explained by an 
alternative diagnosis.  
 
The radiological hallmark is of peri-articular erosions (FIGURE 3) but modern 
management of RA is predicated on early treatment, well before radiological 
erosions are apparent. Treatment in this pre-HURVLRQ³ZLQGRZRIRSSRUWXQLW\´LV
now known to be associated with significant reductions in morbidity and long-
term disabilLW\DQGLQVRPHSDWLHQWVFDQHYHQOHDGWR³VZLWFKLQJRII´WKHV\VWHPLF
inflammation altogether. 
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Treatment begins as soon as possible after the onset of symptoms. A zero-
tolerance approach to inflammation is adopted ± the so-called µWUHDWWRWDUJHW¶
approach where the target is disease remission. Disease modifying anti-
rheumatic drugs (DMARDs) such as Methotrexate, Hydroxycholorquine, 
Sulfasalazine and Leflunomide are commenced early, and in combination. If 
inflammation continues, biologic drugs ± typically anti-TNF drugs (multiple 
examples now commonly used), B-cell depletion therapy (Rituximab), anti-IL6 
drugs (Tocilizumab) or inhibitors to co-stimulatory molecules (Abatacept) ± are 
commenced within 3-6 months of onset. Biologic drugs are usually prescribed 
concurrently with at least one DMARD. The major adverse effect of the biologic 
anti-rheumatic drugs is the increased risk of infection and patients presenting 
unwell on such therapy must be carefully evaluated. 
 
The clinical multi-disciplinary team remains key to management of patients with 
RA. Physiotherapy, podiatry and occupational therapy are important adjuncts to 
pharmacological treatment. Patients are at increased risk of osteoporosis and 
cardiovascular disease and should be actively screened for both. Despite 
modern therapy, patients still require surgical intervention and close liaison 
between rheumatologist and orthopaedic surgeon is crucial. Management of drug 
therapy peri-operatively should be discussed in each case, but the basic principle 
is that DMARDs continue throughout. Guidance from the British Society for 
Rheuamtology (2010) suggests suspending biologic therapy 3-5x the half-life of 
that agent prior to surgery. The American College of Rheumatology, in 
association with the American College of Hip & Knee Surgeons (2017) have 
released specific guidance for patients undergoing elective total hip or total knee 
arthroplasty, suggesting withholding the biolofic agent prior to surgery and 
scheduling the procedure at the end of the dosing cycle for that specific agent. 
The agent should then be restart edonce the wound shows evidence of healing, 
the staples are out, there is no significant swelling, erythema, or drainage, and 
there is no clinical evidence of non-surgical site infections. This would typically be 
around 14 days post-operative. This guidance also suggesting continuing the 
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pre-operative dose of glucocorticoids rather than administering peri-operative 
supra-physiological doses.  
 
Biologic therapy should cease at a time three to five times the half-life for the 
relevant drug prior to surgery and be recommenced 2 weeks later, or when 
wounds are healed.  
 
Consideration of joint replacement in inflammatory arthritis is the same as 
osteoarthritis (OA), being based on pain and loss-of-function, rather than 
inflammation. Ideally, inflammation would be controlled prior to surgery, however 
this is not an absolute necessity. It is not anticipated that inflammatory arthritis 
would recur in a replaced joint, as the synovium is removed. Compared to 
patients with OA, RA patients are at increased risk of dislocation following total 
his arthroplasty (THA) and increased risk of infection following total knee 
arthroplasty (TKA). RA itself is an independent risk factor for infection, in addition 
to the use of immunosuppressive therapy, such as corticosteroids or DMARDs. 
 
SPONDYLOARTHRITIS 
 
The spondyloarthritides include Ankylosing Spondylitis, Psoriatic Arthritis, 
Inflammatory Bowel Disease-associated (formerly enteropathic) arthritis and 
Reactive Arthritis. All can be associated with the HLA B27 tissue-type, although 
this association is strongest in Ankylosing Spondylitis (AS) where up to 95% 
patients are HLA B27 positive. In AS, symptoms typically first occur in the early 
twenties, although average diagnosis lags 10 years behind the onset of 
symptoms. Men are affected three times more commonly than women, and may 
have a more severe phenotype. 
 
There is much clinical overlap amongst the spondyloarthritides - peripheral 
inflammatory arthritis, enthesitis, spinal inflammation (often sacroiliitis) and the 
extra-articular manifestations of inflammatory eye disease (anterior uveitis), skin 
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psoriasis and inflammatory bowel disease (Crohn¶s, Ulcerative colitis) can occur 
across all sub-types. Treatment however is targeted according to the clinical 
features present in an individual patient. 
 
Recent diagnostic criteria have acknowledged this overlap between the 
FRQGLWLRQVDQGDOORZHGIRUDJHQHULFGLDJQRVLVRI³VSRQG\ORDUWKULWLVZLWKD[LDO
VSLQDOLQYROYHPHQW´RU³VSRQG\ORDUWKULWLVZLWKSHULSKHUDOLQYROYHPHQW´Table 1). 
The key shift in emphasis is that radiological evidence of sacroiliitis on plain film 
does not have to be present for diagnosis of axial disease; this is now recognised 
as a late sequelae. Synovitis/ bone oedema of the sacroiliac joint on MRI is now 
taken as the diagnostic standard, with or without inflammatory lesions e.g. 
Romanus lesions (fatty change at anterior vertebral corners) higher up the spine 
(FIGURE 4).  
 
Clinically, axial spondyloarthritis presents with inflammatory back pain (Box 1) 
and peripheral spondyloarthritis presents with arthritis, enthesitis (eg plantar 
fasciitis, achilles tendonitis), or dactylitis (sausage digit). Symptoms tend to 
respond to non-steroidal anti-inflammatory drugs [NSAIDs] and there may be a 
family history of one of the related conditions. Inflammatory markers can be 
elevated but, unlike rheumatoid arthritis, it is not unusual for them to remain 
normal throughout.  
 
Peripheral spondyloarthritis is treated with DMARDs, escalating to biologic 
therapy in much the same way as RA. Axial spondyloarthritis does not respond to 
DMARDs; patients with axial disease move from regular NSAIDs straight to 
biologic treatment. Even in patients with long-standing disease, biologic drugs 
KDYHGHPRQVWUDWHGWKDWGLVHDVHZHSUHYLRXVO\ODEHOOHGDV³EXUQW-RXW´can in fact 
still be active. Care has to be taken to elicit complications of long-standing 
disease, such as cardiorespiratory problems (aortic regurgitation, apical lung 
fibrosis) and neurological sequelae of spinal disease (usually compressive). 
Patients are at increased risk of osteoporosis and cardiovascular disease just like 
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their counterparts with RA. Established biologic drugs for spondyloarthritis 
remain the anti-TNF group. Recent work has demonstrated the importance of the 
IL12/23 and IL17 axis, leading to the development of newer biologic drugs such 
as anti IL-17 (Secukinumab), which is now recommended by NICE for axial 
disease and anti IL-12/23 (Ustekinumab) which  is effective for peripheral 
disease and shows promise for axial involvement..  
 
The rheumatological multi-disciplinary team is again very important. These 
patients tend to be young and have a whole working and family life ahead of 
them. Continued physiotherapy review and occupational therapy input with an 
emphasis on workplace advice are key.  
 
JUVENILE IDIOPATHIC ARTHRITIS 
 
Inflammatory arthritis affects around 1 in every 1000 children and in 
contemporary terminology is juvenile idiopathic arthritis (JIA) rather than the 
historical descriptions of juvenile rheumatoid arthritis or juvenile chronic arthritis. 
The diagnosis of JIA is essentially clinical and made when a child under 16 
presents with joint inflammation persisting for at least 6 weeks where other 
conditions, such as infection and malignancy, have been excluded.  
 
JIA is a heterogeneous group of disorders with seven subtypes classified 
according to the number of joints involved and the pattern of symptoms (Table 2). 
It can be a serious and disabling condition complicated by joint destruction, 
impaired joint function, limitation of growth and osteoporosis. There are also 
significant effects on the emotional and social well being of a child with JIA - 
school attendance may be adversely affected with the attendant loss of 
educational or vocational opportunities and peer relationships. In common with 
other chronic illnesses, a diagnosis of JIA can also have effects on family 
dynamics and impact on all members of the family. Delayed diagnosis is 
common, not least because young children rarely complain of pain and are often 
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presented with non-specific complaints such as limps or because they are not 
walking or moving properly. It is only if and when they are examined that 
synovitis becomes apparent. JIA is significantly associated with chronic anterior 
uveitis and all children and young people with JIA should have regular 
ophthalmic screening. Delaying a diagnosis of JIA may mean missing a 
potentially reversible cause of blindness. 
 
 
Treatment of JIA is symptomatic with intra-articular steroid injections alone in 
oligoarthritis, escalating to systemic treatment with methotrexate and biologic 
drugs in more aggressive forms. It is important to recognise that 40-60% of 
children with JIA have continued arthritis into adulthood. Good coordination and 
transitional planning between paediatric rheumatology and orthopaedic services 
is critical in the care of these young people. 
 
 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
 
This immune complex mediated, multisystem disease often presents with 
arthralgia rather than frank inflammatory arthritis, although the latter can be a 
clinical feature. There is a recognised deforming arthritis ± -DFFRXG¶VDUWKULWLV± 
that can occur. Phenotypically, it resembles rheumatoid arthritis but typical 
erosive RA changes on XR are absent. The pathology is thought to be fascial 
and tendon fibrosis rather than synovitis and patients tend to maintain function 
with relatively few symptoms.  
 
CONCLUSION 
 
Arthritis is common and potentially disabling. In an era of new, effective 
treatments, prompt recognition and referral to rheumatologists of inflammatory 
arthritis in both children and adults is key. Equally important is the prompt and 
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appropriate referral of patients with joint failure by rheumatologists and general 
practitioners for surgical management. Both the medical and surgical 
management of arthritis should be within part of a multidisciplinary team involving 
physiotherapists, occupational therapists and nurses. Clear channels of 
communication and joint working between medical and surgical musculoskeletal 
GLVFLSOLQHVLVLQSDWLHQWV¶EHVWLQWHUHVWV 
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Table 1. ASAS (Assessment of Spondyloarthritis International Society) Classification Criteria for axial 
spondlyloarthritis (SpA) in patients with back pain for more than 3 months and age at onset of less than 45 
years (Rudwaleit M et al. Ann Rheum dis 2009;68:777-83) 
 
*Sacroiliitis on imaging ^SpA Features 
MRI 
Active inflammation highly suggestive of 
sacroiliitis associated with SpA 
 
Inflammatory Back Pain 
Arthritis 
Enthesitis (heel) 
Dactylitis 
Uveitis 
Psoriasis 
&URKQ¶VFROLWLV 
Good response to NSAIDs 
Family history of SpA 
HLA B27 
Elevated CRP 
Plain Xray 
Definite sacroiliitis as defined by modified NY 
criteria 
6DFURLOLLWLVRQLPDJLQJ$1'6S$IHDWXUHA25+/$%$1'RWKHU6S$IHDWXUHVA 
 
 
Box 1.  ASAS (Assessment of Spondyloarthritis International Society) Criteria for Inflammatory Back Pain 
(Sieper J et al. Ann Rheum Dis 2009;68:784-8) 
 
Back pain of more than 3 months duration is inflammatory if: 
x Age at onset less than 40 years 
x Insidious onset 
x Improvement with exercise 
x No improvement with rest 
x Pain at night (with improvement on getting up) 
 
The criteria are fulfilled if at least 4 out of 5 parameters are present 
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CAPTIONS 
 
Figure 1. X-ray of right knee showing severe joint space narrowing with osteophytes and 
subchondral cysts 
 
Figure 2. X-ray of both knees with typical chondrocalcinosis in menisci, spiking of tibial spines 
and preservation of joint spaces 
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Figure 3. X-ray of both hands showing severe symmetrical erosive arthropathy with involvement 
of wrist, metacarpophalangeal and proximal interphalangeal (PIP) joints. Fused intercarpal joints 
and secondary OA in several PIP joints 
 
Figure 4. Magnetic resonance image of sacroiliac joints showing florid marrow oedema on both 
sides of the joints. 
 
